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Abstract
Background: Ghrelin is an orexigenic stomach hormone that acts centrally to increase mid-brain dopamine
neurone activity, amplify dopamine signaling and protect against neurotoxin-induced dopamine cell death in the
mouse substantia nigra pars compacta (SNpc). In addition, ghrelin inhibits the lipopolysaccharide (LPS)-induced
release of pro-inflammatory cytokines from peripheral macrophages, T-cells and from LPS stimulated microglia. Here
we sought to determine whether ghrelin attenuates pro-inflammatory cytokine release from dopaminergic
neurones.
Findings: The dopaminergic SN4741 cell-line, which derives from the mouse substantia nigra (SN) and expresses
the ghrelin-receptor (growth hormone secretagogue receptor (GHS-R)) and the ghrelin-O-acyl transferase (GOAT)
enzyme, was used to determine the neuro-immunomodulatory action of ghrelin. We induced innate immune
activation via LPS challenge (1 μg/ml) of SN4741 neurones that had been pre-cultured in the presence or absence
of ghrelin (1, 10, 100 nM) for 4 h. After 24 h supernatants were collected for detection of IL-1 beta (IL-1β ), TNF
alpha (TNF-α) and IL-6 cytokines via enzyme linked immunosorbent assay (ELISA) analysis. Nuclear translocation of
the transcription factor nuclear factor kappa B (NF-κB) was analyzed by Western blotting, and to determine viability
of treatments a cell viability assay and caspase-3 immunohistochemistry were performed.
We provide evidence that while IL-1β and TNF-α were not detectable under any conditions, SN4741 neurones
constitutively released IL-6 under basal conditions and treatment with LPS significantly increased IL-6 secretion.
Pre-treatment of neurones with ghrelin attenuated LPS-mediated IL-6 release at 24 h, an affect that was inhibited
by the GHS-R antagonist [D-Lys3]-GHRP-6. However, while ghrelin pre-treatment attenuated the LPS-mediated
increase in NF-κB, there was no alteration in its nuclear translocation. Cell viability assay and caspase-3
immunocytochemistry demonstrated that the results were independent from activation of cytotoxic and/or
apoptotic mechanisms in the neuronal population, respectively.
Conclusion: Our results provide evidence that the gut-hormone, ghrelin, attenuates IL-6 secretion to LPS challenge
in mid-brain dopaminergic neurones. These data suggest that ghrelin may protect against dopaminergic SN nerve
cell damage or death via modulation of the innate immune response.
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Findings
Ghrelin is secreted from the stomach in response to
nutrient restriction [1] and signals changes in metabolic
status to the brain [2]. Circulating ghrelin crosses the
blood–brain barrier (BBB) and binds to its receptor,
growth hormone secretagogue receptor (GHS-R), in sev-
eral brain regions, including the substantia nigra (SN)
[3], where it modulates the activity and synaptic
organization of midbrain dopamine neurones [4]. Of
particular interest, the GHS-R has been shown to co-
localize in the brain with the dopamine receptor 1
(D1R), and these receptors heterodimerize in-vitro to
potentiate dopamine-induced cAMP accumulation [5].
In in vitro and rodent models of Parkinson’s disease
(PD), acute ghrelin antagonizes 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced toxicity in
dopaminergic neurones of the mouse SN [6,7]. More re-
cently, ghrelin and GHS-R knock-out animals displayed
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increased susceptibility to dopamine loss in the substantia
nigra pars compacta (SNpc) following MPTP administra-
tion [8].
In addition to modulating dopamine function in mid-
brain neurones, ghrelin has also been described as an
anti-inflammatory hormone [9], inhibiting the release of
pro-inflammatory cytokines in response to treatment
with the bacterial endotoxin, lipopolysaccharide (LPS),
in peripheral macrophages [10] and T-cells [11]; as well
as from central nervous system (CNS) derived microglia
[12]. Moreover, in the same study, exogenous ghrelin
suppressed spinal cord levels of TNF-α, IL-1β and IL-6
mRNA in a mouse model of experimental autoimmune
encephalomyelitis (EAE). As markers of inflammation
have been observed in human PD [13] and peripheral
[14] and striatal [15] LPS administration result in in-
flammation and degeneration of tyrosine hydroxylase
(TH) immunopositive cells in the SNpc of adult rats,
respectively, we sought to determine whether ghrelin’s
neuromodulatory effect may involve attenuation of pro-
inflammatory cytokine release from mid-brain dopamin-
ergic neurones.
First, we established the mouse mid-brain derived
SN4741 cell-line [16] as an appropriate cellular system
to study ghrelin’s neuronal actions. Cells (5 × 104 per
ml; Scepter, Millipore, Billerica, MA, USA) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco, Life Technologies, Paisley, UK) containing 10%
fetal bovine serum (Gibco), 3% filtered glucose (Sigma,
St Louis, MO, USA) and 1% L-Glutamine penicillin
streptomycin (Sigma) at 37°C in air with 5% CO2, in 96-
well plates (Corning, Tewksbury, MA, USA) for 24 h.
Cells were fixed and processed according to the manu-
facturer’s instructions (NeuroTox-3, Millipore) prior to
staining for the markers βIII-tubulin (rabbit polyclonal,
Millipore, 1:100), GHS-R (goat polyclonal, Santa Cruz
Biotechnology, Santa Cruz, CA, USA, 1:200), GOAT (rabbit
polyclonal Phoenix Pharmaceuticals Inc, Burlingame, CA,
USA, 1:500), GFAP (mouse monoclonal, Millipore, 1:100),
TH (rabbit polyclonal, Abcam, Cambridge, UK, 1:500),
and the cytotoxic marker, caspase-3 (rabbit polyclonal,
Promega, Southampton, UK, 1:250) for 1 h at room
temperature. Followed by incubation with appropriate
secondary antibody FITC-donkey anti-rabbit (Millipore,
1:200), Cy3-donkey anti-mouse (Millipore, 1:200), AF-568-
donkey anti-goat (Life Technologies, Paisley, UK, 1:200)
and Hoechst nuclear stain (5 μg/ml) for 1 h at room
temperature protected from light. Fluorescent images,
captured using a x20 objective on an In Cell Analyser
2000 (GE Healthcare, Cardiff, UK), demonstrated im-
munoreactivity for the neuronal marker, βIII-tubulin
(Figure 1A); the rate-limiting enzyme for dopamine
synthesis, TH (Figure 1B); the ghrelin receptor, GHS-R
(Figure 1C); and the enzyme for ghrelin acylation, GOAT
(Figure 1D); thus confirming the suitability of this cell line
to investigate ghrelin function. No immunoreactivity was
DC
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Figure 1 Mouse mid-brain derived SN4741 cells express GHS-R, GOAT, BIII-tubulin and TH. To determine whether SN4741 neurones were
an appropriate cellular system to study ghrelin’s neuronal actions, we performed immunofluorescence (IF) to establish expression of key proteins.
SN4741 cells were immunoreactive for βIII-tubulin (A), TH (B), GHS-R1a (C) and GOAT (D). No immunoreactivity was observed for the glial marker,
GFAP (A). For all negative controls the primary antibodies were excluded from the staining procedure. In addition, specificity of the GOAT
antibody has been confirmed using an antibody-specific blocking peptide (Phoenix peptide cat.no 032–12; personal communication, Dr T Wells).
The images are representative of three independent experiments performed with three replicates for each antigen.
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observed for the glial marker, GFAP (Millipore)
(Figure 1A).
To determine whether SN4741 neurones constitutively
release inflammatory cytokines and whether ghrelin
modulates their secretion in response to endotoxin chal-
lenge, cells (2 to 5 × 104 per ml) were grown in 24-well
plates, cultured as before and treated with acyl-ghrelin
(Phoenix Pharmaceuticals cat.no. 031–31: 1, 10, 100
nM) for 4 h prior to LPS (1 μg/ml, Ultrapure LPS E. coli
0111:B4, Invivogen, San Diego, CA, USA) challenge.
This dose of LPS is consistent with previously published
work [8]; moreover, higher doses (2 μg and 10 μg) did
not further augment IL-6 secretion in SN4741 cells (data
not shown). Supernatants were collected 24 h later for
detection of the pro-inflammatory cytokines TNF-α,
IL1-β and IL-6 via ELISA (DuoSet, R&D Systems,
Abingdon, UK) according to the manufacturer’s in-
structions. While TNF-α and IL1-β were not detectable
under any conditions, SN4741 neurones constitu-
tively released IL-6 and augmented its release in re-
sponse to LPS (Figure 2A). This supports previous
data suggesting that neurones are capable of mediating
inherent cytokine responses via the synthesis and secre-
tion of IL-6 [17]. Pre-treatment of neurones with ghrelin
resulted in the significant attenuation of LPS-mediated
IL-6 release (Figure 2A). Subsequently, to establish
whether ghrelin inhibits LPS-induced IL-6 release via
activation of its receptor, GHS-R, cells were pre-
incubated in the presence of the selective GHS-R
antagonist, [D-Lys3]-GHRP-6 (1,000 nM). Subsequent
collection of supernatant and ELISA for IL-6 showed
that ghrelin-mediated inhibition of LPS-induced IL-6
was prevented by the presence of [D-Lys3]–GHRP-6
(Figure 2B). To determine whether ghrelin (100 nM)
and LPS treatment (as above) regulated gene expression
of IL-6 and toll-like receptor 4 (TLR4), total RNA was
extracted (Norgen Biotek, Thorold, ON, Canada; cat. no.
23000, according to the manufacturer’s instructions)
from SN4741 cell lysates (n = 3 per group, from two in-
dependent experiments) at the 24 h time point. Subse-
quent RT-qPCR and melt-curve analysis confirmed the
expression of IL-6 and TLR4 in SN4741 cells (mouse IL-6
forward primer TCCATCCAGTTGCCTTCTTG, reverse
primer GGTCTGTTGGGAGTGGTATC; mouse TLR4
forward primer CTGGCTAGGACTCTGATCATG, re-
verse primer GCATTGGTAGGTAATATTAGGAACTA;
Primer Design, Southampton, UK). Using the ΔΔCt
method, quantification of IL-6 and TLR4 with individual
samples normalized to β-actin expression (Primer Design),
which demonstrated invariant expression between sam-
ples, showed that IL-6 and TLR4 mRNA levels were not
altered (that is, greater than a two-fold change relative to
control) by ghrelin or ghrelin/LPS co-treatments. How-
ever, LPS treatment alone induced a 2.03-fold and 2.76-
fold reduction in the level of IL-6 and TLR4 mRNA, re-
spectively. This may represent a negative feedback re-
sponse to limit the potential detrimental consequences of
excess IL-6 and TLR4 signaling in these neurones and is
consistent with the phenomenon of LPS-tolerance ob-
served in peritoneal macrophages [18].
To ensure culture treatments were not inducing cyto-
toxic changes in the SN4741 neurones, cell viability was
assessed using the CellTiter Blue assay (Promega)
performed according to the manufacturer’s instructions.
Briefly, cells were cultured with ghrelin followed by LPS
stimulation prior to incubation with CellTiter-Blue re-
agent for 13 h at 37°C. Absorbance readings at 570 to
600 nm using POLARstar Omega plate Reader (BMG
Labtech, Aylesbury, UK) showed that culture treatments
did not induce cytotoxic changes (Figure 2C). Further-
more, there was no alteration in the nuclear intensity of
the apoptotic marker, caspase-3, in SN4741 cells follow-
ing the same treatments (Figure 2D). The presence of
nuclear caspase-3, which is dependent on its proteolytic
activation [19], was detected by immunofluorescence
and quantified using In Cell Analyser Developer™ soft-
ware (GE Healthcare). Briefly, nuclear intensity images
were acquired using a X10 objective and a watershed
segmentation algorithm was used to distinguish individ-
ual nuclei; detected binary objects less than 40 μm2 and
greater than 200 μm2 were subsequently removed from
the analysis to reduce false and double counting of
viable nuclei respectively.
Finally, protein levels of the transcription factor NF-κB,
previously implicated in the ghrelin-mediated inhibition
of cytokine release in human endothelial cells [20] and
murine macrophages [10], were analyzed by Western
blot in nuclear and cytoplasmic cell extracts. SN4741
cells were seeded at 4 × 104 per ml and grown under
normal conditions for 24 h prior to overnight incubation
in serum free media. Cells were pre-treated in the pres-
ence or absence of acyl-ghrelin (100 nM) or [D-Lys3]-
GHRP-6 (1,000 nM) for 4 h prior to LPS (1 μg/ml)
stimulation for 2 h.
Cytoplasmic and nuclear proteins were extracted
(Nuclear Extract Kit, Active Motif, Carlsbad, CA, USA)
and protein concentration determined by DC Protein
Assay (Bio-Rad Laboratories, Hertfordshire, UK). Lysates
(5 μg) were mixed with Laemmli Lysis Buffer (Sigma, St.
Louis, MO, USA) in a 1:1 ratio and heated at 95°C to de-
nature proteins. Samples were briefly spun down and
proteins separated using 12% SDS-PAGE (Expedeon,
Cambridgeshire, UK) gel electrophoresis and transferred
to a PVDF membrane at 200 V for 75 minutes.
Membranes were blocked with 3% milk (in TBST) for 60
minutes at room temperature with mild agitation to re-
duce non-specific binding then probed for the p65 sub-
unit of the NF-ĸB complex (rabbit polyclonal, Santa
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Cruz Biotechnology, sc-372, used at 1:1,000) and the
loading control β-tubulin (rabbit polyclonal, Abcam,
Cambridge, UK, ab6046, used at 1:500) for 90 minutes
at room temperature with mild agitation. Subsequently,
membranes were incubated with horseradish peroxidase-
conjugated secondary antibody (goat polyclonal to rabbit
IgG, Abcam, ab6721, used at 1:2,000) for 45 minutes at
room temperature with mild agitation. Immunoreactive
protein bands were visualized using the enhanced chemilu-
minescence system (Immun-star WesternC Chemilumines-
cent kit, Bio-Rad Laboratories, Hertfordshire, UK) after a
15-second exposure and protein content was normalized to
the loading control, β-tubulin. Under basal conditions p65
was abundant in the cytoplasmic extract (Figure 3a),
LPS(1ug/ml) - +                 +                +
Ghrelin(100nM) - - +                +
[D-Lys3]GHRP-6  - - - +
LPS(1ug/ml) - - +           +           +           +
Ghrelin(1nM)       - - - +           - -
Ghrelin(10nM)    - - - - +           -
Ghrelin(100nM) - + - - - +
A B
LPS(1ug/ml) - - +           +           +           +
Ghrelin(1nM)       - - - +           - -
Ghrelin(10nM)    - - - - +           -
Ghrelin(100nM) - + - - - +
D
LPS(1ug/ml) - - + + + + - -
Ghrelin(1nM) - - - + - - - -
Ghrelin(10nM) - - - - + - - -
Ghrelin(100nM) - + - - - + - -
DMSO (50%) - - - - - - + -
No cells - - - - - - - +
C
****
Figure 2 Ghrelin inhibits LPS-induced IL-6 release in a GHS-R dependent manner. To determine whether ghrelin modulates the secretion
of inflammatory cytokines in mid-brain neurones, we induced innate-immune activation via LPS (1 μg/ml). Neurones (3 to 5 x 105 per ml) were
treated with ghrelin (1, 10, 100 nM) for 4 h prior to LPS (1 μg/ml) challenge; subsequently, supernatants were collected 24 h later for detection of
IL-6 via ELISA. A) Pre-treatment with ghrelin at 1, 10, and 100 nM significantly reduced LPS-induced IL-6 secretion. Data are normalized to cell
number and expressed as a percentage of the control value (mean ± s.e.m), which was 774.8 ± 306.7 pg/ml, and represent four independent
experiments performed in-triplicate for each concentration point. B) Pre-incubation of ghrelin with the ghrelin-receptor antagonist, [D-Lys-3]-
GHRP-6, blocked ghrelin’s inhibitory effect on LPS-induced IL-6 secretion. The data (expressed as in A) with a control value of 815.8 ± 319.8 pg/ml
represent the mean ± s.e.m of five independent experiments performed with four replicates for each concentration point. To ensure that
treatments were not inducing cytotoxic or apoptotic changes in SN4741 cells, we tested cell viability (CellTiter Blue, Promega) (C) and caspase-3
immunoreactivity (D). The CellTiter-BlueW Assay, which is based on the ability of living cells to convert a redox dye (resazurin; Absorbancemax =
605 nm) into a fluorescent end product (resorufin; Absorbancemax = 573 nm) (viable cells reduce resazurin into resorufin) demonstrated that
ghrelin and LPS had no significant effect on viability (C). Similarly, nuclear intensity of caspase-3 was not significantly altered by treatments (D).
The data represent the mean ± SEM of two independent experiments with seven replicates for each concentration point. Statistical analysis was
performed using one-way ANOVA with Dunnett’s multiple comparison. P <0.05 regarded as significant (*P <0.05; ***P <0.001; ****P <0.0001 vs LPS).
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whereas ghrelin treatment seemingly promoted shuttling of
p65 into the nuclear compartment (Figure 3b). However,
while LPS treatment alone elevated p65 in both cytoplas-
mic and nuclear compartments (Figure 3c), and pre-
treatment with ghrelin and [D-Lys3]-GHRP-6 attenuated
p65 (Figure 3d, e), there was no apparent alteration in the
cytoplasmic to nuclear ratio to indicate regulation via p65.
This suggests that ghrelin’s inhibitory effect on IL-6
release from mid-brain dopamine neurones may not be
associated with NF-κB nuclear translocation. Given previ-
ous findings [10,20] we cannot rule out the possibility that
1 μg/ml LPS represents a sub-maximal dose for NF-κB
nuclear translocation or that such translocation is tempor-
ally regulated. Alternatively, the NF-κB response to LPS
was analyzed in midbrain neurones in the absence of as-
trocytes and may, therefore, indicate an alternative mech-
anism of IL-6 regulation for this cell population. Another
possibility, consistent with unaltered levels of IL-6 gene
expression, is that the observed inhibitory action of
ghrelin may be mediated by modulating secretory vesicle
physiology rather than transcriptional mechanisms.
Conclusion
Given that circulating ghrelin crosses the BBB, binds to
its receptor in the SNpc [3] and protects against dopa-
mine nerve cell death in toxin-models of PD [6,7], we
suggest that ghrelin is an endogenous neuro-active
hormone that plays a key role in the brain’s adaptation
to nutrient supply. We provide evidence that ghrelin’s
effect on dopamine mid-brain neurones may be medi-
ated, at least in part, via directly modulating IL-6 release.
These data are consistent with ghrelin protecting against
dopamine neurone death via inhibition of microglial
activation [21] and suggest that ghrelin may confer
protection via the modulation of neurone-glia commu-
nication [22]. Moreover, as circulating post-prandial
ghrelin is significantly reduced in PD patients [23] and
cerebrospinal fluid levels of IL-6 are increased in both
juvenile and adult onset PD [24,25], we speculate that a
reduction in circulating ghrelin may exacerbate dopa-
minergic cell loss in human PD due to elevated IL-6 act-
ing as a primer for neurodegeneration. However, as IL-6
is a pleiotropic cytokine with mitogenic and neuro-
trophic actions, the potential for ghrelin protecting
against dopaminergic SN nerve cell damage or death via
attenuated IL-6 requires further in-vivo elucidation.
In conclusion, we describe a previously uncharacterized
innate-immune response within mesencephalic neurones
whereby an endogenous brain-penetrant hormone that is
regulated by feeding, inhibits neuronal cytokine secretion
in response to immune-challenge.
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